A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma
Clinical trial NCT06464185 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06464185
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-04-30
- Primary completion
- 2026-03-30
- Enrollment
- 53
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.